iShares Morningstar Small-Cap Growth ETFISCG

The iShares Morningstar Small-Cap Growth ETF (ISCG) is a wrapper around 200 small-cap US stocks selected by Morningstar for their growth potential, not for their ability to deliver blockbuster returns. The fund’s mandate is simple: own companies with market caps between $500 million and $2 billion that Morningstar believes have above-average earnings growth prospects. That’s the entire sales pitch-no AI, no revolution, just a fee-driven bet on small fry (source: iShares official ETF centre, https://www.ishares.com/).

ISCG trades on the Nasdaq under the ticker ISCG, which means it’s as liquid as a puddle on a quiet Tuesday. The fund’s expense ratio is 0.06%, or $6 for every $10,000 invested-a bargain if you believe the fund will relative strength its index by more than 0.06% a year, which is like hoping a hamster will win the Kentucky Derby. The issuer marketing leans hard on “innovation” and “expert management,” but the actual product is a passive slice of the small-cap growth universe, tracked by Morningstar’s index methodology (source: Nasdaq market activity, https://www.nasdaq.com/market-activity/etf/iscg).

According to the SEC filing, ISCG is domiciled in the US and registered under the Investment Company Act of 1940. The fund’s prospectus states it seeks to track the Morningstar® US Small-Moat TR USD index, which is a rules-based index that screens for small-cap stocks with “economic moats” and growth characteristics. The index methodology is public, but the fund’s tracking error is not-meaning you can’t know how closely it hugs the index until the fact sheet drops. The issuer warns that most UK protections don’t apply, which is a polite way of saying if BlackRock messes up, you’re on your own (source: SEC EDGAR fund search for ISCG, https://www.sec.gov/edgar/search/#/q=ISCG).

ISCG’s top holdings are a who’s who of small-cap obscurity: think regional banks, niche software firms, and medical-device makers that sound important until you realise their combined weight in the portfolio is less than 5%. The fund’s liquidity is decent for a small-cap ETF, but don’t expect to trade it like an S&P 500 tracker. The Nasdaq page shows average daily volume under 100,000 shares, which is thin enough that a whale could move the price before breakfast. The issuer’s UK disclaimers are lengthy, but the core message is consistent: this is a niche product with niche risks and a fee that’s small only in absolute terms (source: Nasdaq market activity, https://www.nasdaq.com/market-activity/etf/iscg; iShares UK - BlackRock, https://www.ishares.com/uk/individual/en/products/ai-etfs).

The fund’s marketing leans into AI and innovation, but the portfolio is a sprawling mosaic of small-cap growth stocks that may or may not have anything to do with artificial intelligence. The issuer’s “Get started with AI ETFs” page is a masterclass in thematic bait-and-switch: it claims to “capture AI’s potential growth,” but ISCG’s holdings are a grab-bag of small-cap firms, most of which are not AI pure-plays. The fund’s prospectus makes no guarantee that the index it tracks is even AI-heavy-it’s just small-cap growth, full stop. The images of machinery and overpasses are there to distract you from the fact that you’re paying a fee to own a slice of the small-cap market’s also-rans (source: iShares UK - BlackRock, https://www.ishares.com/uk/individual/en/products/ai-etfs; Get started with AI ETFs | iShares, https://www.ishares.com/uk/individual/en/products/ai-etfs?switchLocale=y&siteEntryPassthrough=true).